OHI · Omega Healthcare Investors Inc
$46.97
+0.02 (+0.04%)
At close · Aug 26
Market Cap
$14.25B
Shares
303.01M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$46.97
Open$47.12
Day$46.79–47.23
52W close$39.41–51.72
Avg vol 30d1.9M
Short int12.2M · 4.0% float · 6.8d
Short vol64%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very Low
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−3%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
61%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
0%
trailing
YTD return
+6%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $48 › 200d $46 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +87 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.02% of float · ▼ -5.4% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
758 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+13%
Y/Y
EPS growth
+25%
Y/Y
Valuation
P/E 16.7
below peers
Buyback
$500.0M
authorized
Balance sheet
$4.2B
net debt
Quant / Vol
risk profile
Volatility
21%
annualized · 1-yr
Max drawdown
−12%
past year
ATR
1.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Asset sales
· quarterly 2026
$15M – $25M
Prior guidance
period ended
· from the 8-K filed Oct 30, 2025
Adjusted FFO (AFFO) per share
· full year 2025
$3.08 – $3.10
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
61%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $48 › 200d $46 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +87 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.02% of float · ▼ -5.4% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
758 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $39
Now $47 · 61%
Range high $52
vs 200-day avg +2%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted FFO per diluted share non-GAAP | $0.83 | Q2 2026 | — |
|
|
|||
| Adjusted Funds From Operations non-GAAP | $261M | Q2 2026 | — |
|
|
|||
| Common shares issued | 1.3M | Q2 2026 | — |
| FAD per diluted share non-GAAP | $0.78 | Q2 2026 | — |
|
|
|||
| Funds Available for Distribution non-GAAP | $248M | Q2 2026 | — |
|
|
|||
| Net Operating Income non-GAAP | $331M | Q2 2026 | — |
| New investments completed | $126M | Q2 2026 | — |
|
|
|||
| Quarterly common dividend | $0.68 | August 2026 | — |
| Saber facilities leased from Company | 69 | Q2 2026 | — |
| Saber JV contractual rent per annum | $83.1M | Q2 2026 | — |
| Saber JV number of facilities | 71 | Q2 2026 | — |
| Saber JV weighted average interest rate | 5.6% | Q2 2026 | — |
| Saber PropCo JV net investment activity | $124.3M | Q2 2026 | — |
| Weighted-average common shares outstanding | 316M | Q2 2026 | — |
|
|
|||
| Common shares issued (gross proceeds) | $107M | Q1 2026 | — |
| CommuniCare facilities expected sale price | $480M | Q2 2026 | — |
| Investments in unconsolidated entities | $97M | Q1 2026 | — |
| Nareit funds from operations available per share non-GAAP | $0.79 | Q1 2025 | — |
| Quarterly cash dividend declared | $0.67 | as of April 23, 2026 | — |
| Real estate acquisitions | $126M | Q1 2026 | — |
| Real estate loan fundings | $27M | Q1 2026 | — |
| Saber JV contractual rent | $5.4M | as of March 31, 2026 | — |
| Saber JV number of facilities leased | 53 | as of March 31, 2026 | — |
| Saber OpCo annualized yield | 8% | Q1 2026 | — |
| Saber OpCo equity interest | 9.9% | January 2026 | — |
| Saber OpCo JV equity interest acquired | $93M | Q1 2026 | — |
| Saber PropCo JV equity interest | 49% | as of March 31, 2026 | — |
| Saber PropCo JV facilities operated | 65 | as of March 31, 2026 | — |
| Weighted average annual interest rate | 4.2% | as of March 31, 2026 | — |
| Adjusted Funds From Operations (full year) non-GAAP | $946M | FY 2025 | — |
| Aggregate debt repaid (Q4) | $1.27B | Q4 2025 | — |
| ATM Program size (new) | $2B | Q4 2025 | — |
| Delayed draw unsecured term loan facility drawn | $300M | Q4 2025 | — |
| FAD per diluted share (full year) non-GAAP | $2.96 | FY 2025 | — |
| Funds Available for Distribution (full year) non-GAAP | $903M | FY 2025 | — |
| New investments completed (full year) | $1.1B | FY 2025 | — |
| Omega OP Units issued (Q4) | 5.5M | Q4 2025 | — |
| Senior unsecured credit facility size (new) | $2.3B | FY 2025 | — |
| Value of Omega OP Units issued | $222M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OHI
this stock
Omega Healthcare Investors Inc
|
$14.25B | +5.9% | +13.2% | 16.7 | 4.0% |
|
WELL
Welltower Inc.
|
$169.43B | +30.1% | +35.6% | 119.4 | 2.5% |
|
VTR
Ventas, Inc.
|
$47.95B | +20.8% | +18.5% | 173.1 | 4.6% |
|
DOC
Healthpeak Properties, Inc.
|
$14.94B | +34.2% | +4.5% | 61.9 | 3.3% |
|
AHR
American Healthcare REIT, Inc.
|
$12.25B | +21.5% | +9.1% | 81.4 | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OHI | +0.1% | -8.6% | -0.2% | -7.2% | +5.9% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +0.5% | -13.6% | -12.7% | -9.8% | -6.4% |
Capital returns
Latest dividend
$0.68
/ share · ex Aug 3, 2026
Paid (TTM)
$2.69
/ share · 4 payouts
Dividend yield (TTM, derived)
5.73%
Buyback program
· as of Jun 30, 2025
Authorized
$500.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
888491
CUSIP
681936100
13F (30d)
550 filings
545 filers
Visit website
Investor relations